Q3FY18 revenue grew 6% YoY/ 17% QoQ (19%/ 11% YoY decline in Q1/ Q2), 9% ahead of our estimates, on resumption of supplies of non-exempted products and completion of USFDA resolution in Sept-Nov'17.